Hepatitis B Virus Reactivation in a Surface Antigen-negative and Antibody-positive Patient after Rituximab Plus CHOP Chemotherapy.
- Author:
Eui Bae KIM
1
;
Dae Sik KIM
;
Seh Jong PARK
;
Yong PARK
;
Kyoung Ho RHO
;
Seok Jin KIM
Author Information
1. Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. kstwoh@korea.ac.kr
- Publication Type:Case Report
- Keywords:
Rituximab;
Hepatitis B virus;
Lymphoma
- MeSH:
Aged;
Antibodies, Monoclonal, Murine-Derived;
B-Lymphocytes;
DNA;
Female;
Hepatitis;
Hepatitis B;
Hepatitis B e Antigens;
Hepatitis B Surface Antigens;
Hepatitis B virus;
Humans;
Korea;
Lymphoma;
Lymphoma, B-Cell;
Lymphoma, Non-Hodgkin;
Organothiophosphorus Compounds;
Recurrence;
Rituximab
- From:Cancer Research and Treatment
2008;40(1):36-38
- CountryRepublic of Korea
- Language:English
-
Abstract:
Rituximab is a monoclonal antibody that targets B-lymphocytes, and it is widely used to treat non-Hodgkin's lymphoma. However, its use has been implicated in HBV reactivation that's related with the immunosuppressive effects of rituximab. Although the majority of reactivations occur in hepatitis B carriers, a few cases of reactivation have been reported in HBsAg negative patients. However, reactivation in an HBsAg negative/ HBsAb positive patient after rituximab treatment has never been reported in Korea. We present here an HBsAg-negative/HBsAb-positive 66-year-old female who displayed reactivation following rituximab plus CHOP chemotherapy for diffuse large B-cell lymphoma. While she was negative for HBsAg at diagnosis, her viral status was changed at the time of relapse as follows: HBsAg positive, HBsAb negative, HBeAg positive, HBeAb negative and an HBV DNA level of 1165 pg/ml. Our observation suggests that we should monitor for HBV reactivation during rituximab treatment when prior HBV infection or occult infection is suspected, and even in the HBsAg negative/HBsAb positive cases.
